Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Chiba, Urayasu, Japan Clinical Trials

A listing of Chiba, Urayasu, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (50) clinical trials

A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

An open-label, dose-escalation (Part 1), dose-expansion (Part 2) study to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-155 alone and in combination with paclitaxel or docetaxel. In Part 1 (dose escalation), subjects will receive escalating doses of ABBV-155 monotherapy (Part 1a) or ABBV-155 in combination with paclitaxel or ...

Phase

7.35 miles

Learn More »

A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies

Objectives Primary objective: Investigate the safety and tolerability of AZD4635 monotherapy in Japanese patients Secondary objective: Characterize the single-dose and multiple-dose plasma pharmacokinetic (PK) parameters of AZD4635 monotherapy Determine the preliminary anti-tumor activity of AZD4645 monotherapy Overall design: This is a phase I, open-label study of AZD4635 in Japanese patients ...

Phase

7.35 miles

Learn More »

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

This is a phase I/Ib, open label study. The escalation portion will characterize the safety and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior anti-PD-1/PD-L1 therapy, or subjects with NPC. After the determination of the MTD/RD for a particular ...

Phase

7.35 miles

Learn More »

A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)

This is a multicenter, open-label, non-randomized, study of pembrolizumab (PBZ) in combination with cisplatin (CIS) and pemetrexed (PMX) in treatment of nave participants with a histologically confirmed diagnosis of advanced malignant pleural mesothelioma (MPM) in Japanese participants. This study will evaluate the safety, tolerability, and preliminary efficacy of PBZ in ...

Phase

7.35 miles

Learn More »

A Study to Test Different Doses of BI 891065 Alone and in Combination With BI 754091 in Asian Patients With Different Types of Advanced Cancer (Solid Tumours)

The primary objective of this trial is: Part A To determine the Maximum tolerated dose (MTD) and/or the recommended dose (RD) of BI 891065 monotherapy for further development in Asian patients with advanced solid tumours Part B To determine the MTD and/or the RD of BI 891065 in combination with ...

Phase

7.35 miles

Learn More »

A Study of LY3435151 in Participants With Solid Tumors

The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.

Phase

7.35 miles

Learn More »

A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

This is an open-label, multi-center, Phase 1 study of PF-04449913 in Japanese patients. PF-04449913 will be administered orally as a single agent in patients with select advanced hematologic malignancies, or in combination with LDAC [Low-Dose Ara-C] or cytarabine and daunorubicin in previously untreated patients with AML [Acute Myeloid Leukemia] or ...

Phase

7.35 miles

Learn More »

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

The purpose of this study is to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers

Phase

7.35 miles

Learn More »

Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors

The study will determine the recommended Phase 2 dose (RP2D) of ABBV-151 administered as monotherapy and in combination with ABBV-181 as well as to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-151 alone and in combination with ABBV-181. The study will consist of 2 phases: dose escalation and ...

Phase

7.35 miles

Learn More »

This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors)

Phase Ia - The main objective of the dose-escalation part of the trial is to determine the maximum tolerated dose (MTD), based on the frequency of patients experiencing dose limiting toxicities (DLT) during the first treatment cycle, and the recommended dose for expansion (RDE) of BI 907828 monotherapy, and to ...

Phase

7.35 miles

Learn More »